Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
72.39
-0.44 (-0.60%)
Jan 29, 2026, 12:47 PM EST - Market open
Halozyme Therapeutics Employees
Halozyme Therapeutics had 350 employees as of December 31, 2024. The number of employees decreased by 23 or -6.17% compared to the previous year.
Employees
350
Change (1Y)
-23
Growth (1Y)
-6.17%
Revenue / Employee
$3,551,006
Profits / Employee
$1,701,406
Market Cap
8.51B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 350 | -23 | -6.17% |
| Dec 31, 2023 | 373 | -20 | -5.09% |
| Dec 31, 2022 | 393 | 248 | 171.03% |
| Dec 31, 2021 | 145 | 9 | 6.62% |
| Dec 31, 2020 | 136 | 4 | 3.03% |
| Dec 31, 2019 | 132 | -149 | -53.02% |
| Dec 31, 2018 | 281 | 26 | 10.20% |
| Dec 31, 2017 | 255 | -4 | -1.54% |
| Dec 31, 2016 | 259 | 43 | 19.91% |
| Dec 31, 2015 | 216 | 63 | 41.18% |
| Dec 31, 2014 | 153 | -17 | -10.00% |
| Dec 31, 2013 | 170 | 18 | 11.84% |
| Dec 31, 2012 | 152 | 17 | 12.59% |
| Dec 31, 2011 | 135 | 33 | 32.35% |
| Dec 31, 2010 | 102 | -38 | -27.14% |
| Dec 31, 2009 | 140 | 10 | 7.69% |
| Dec 31, 2008 | 130 | 38 | 41.30% |
| Dec 31, 2007 | 92 | 52 | 130.00% |
| Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Jazz Pharmaceuticals | 2,800 |
| Caris Life Sciences | 1,769 |
| Axsome Therapeutics | 816 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 498 |
| Vaxcyte | 414 |
| Rhythm Pharmaceuticals | 283 |
| Krystal Biotech | 275 |
HALO News
- 1 day ago - Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript - Seeking Alpha
- 1 day ago - Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance - PRNewsWire
- 8 days ago - Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - PRNewsWire
- 21 days ago - Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® - PRNewsWire
- 24 days ago - Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - PRNewsWire
- 6 weeks ago - U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer - PRNewsWire
- 6 weeks ago - Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) - Seeking Alpha
- 7 weeks ago - Jim Lang Elected to Halozyme's Board of Directors - PRNewsWire